FY2025 EPS Estimates for AVBP Reduced by Lifesci Capital

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Equities research analysts at Lifesci Capital cut their FY2025 earnings per share (EPS) estimates for ArriVent BioPharma in a research report issued to clients and investors on Monday, March 3rd. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings per share of ($3.97) for the year, down from their previous estimate of ($3.80). The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. Lifesci Capital also issued estimates for ArriVent BioPharma’s FY2026 earnings at ($4.49) EPS.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.18.

Separately, HC Wainwright raised their target price on shares of ArriVent BioPharma from $36.00 to $39.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd.

ArriVent BioPharma Price Performance

AVBP opened at $21.81 on Thursday. ArriVent BioPharma has a 12-month low of $14.35 and a 12-month high of $36.37. The firm has a 50 day moving average of $26.32 and a two-hundred day moving average of $27.12.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in AVBP. Suvretta Capital Management LLC boosted its holdings in ArriVent BioPharma by 21.7% in the 4th quarter. Suvretta Capital Management LLC now owns 2,246,000 shares of the company’s stock worth $59,833,000 after buying an additional 400,838 shares during the last quarter. FMR LLC grew its holdings in ArriVent BioPharma by 8.7% in the 3rd quarter. FMR LLC now owns 2,119,695 shares of the company’s stock valued at $49,813,000 after buying an additional 169,514 shares in the last quarter. Octagon Capital Advisors LP raised its holdings in shares of ArriVent BioPharma by 4.2% during the 4th quarter. Octagon Capital Advisors LP now owns 2,059,387 shares of the company’s stock worth $54,862,000 after acquiring an additional 83,000 shares during the period. Infinitum Asset Management LLC purchased a new stake in shares of ArriVent BioPharma in the fourth quarter valued at about $43,794,000. Finally, Novo Holdings A S increased its position in ArriVent BioPharma by 1.0% during the fourth quarter. Novo Holdings A S now owns 1,520,627 shares of the company’s stock worth $40,510,000 after purchasing an additional 15,312 shares during the last quarter. Hedge funds and other institutional investors own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.